demonstrate

Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis

ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and…

1 week ago

ST Engineering iDirect to Demonstrate Intuition’s Next-Gen Capabilities at Satellite 2025

Witness the power of advanced automation, multi-orbit connectivity and cloud-driven scalability in action   HERNDON, Va., March 5, 2025 /PRNewswire/…

2 weeks ago

Three-Year Results for EYLEA HD (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals

At three years of EYLEA HD treatment, the vast majority of patients maintained visual and anatomic improvements while achieving extended…

1 month ago